Investorideas.com - NASDAQ Biotech News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Presenting at Upcoming Oppenheimer Healthcare Conference and Singular Research Conference

Investorideas.com - NASDAQ Biotech News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Presenting at Upcoming Oppenheimer Healthcare Conference and Singular Research Conference

NASDAQ Biotech company will provide status update on Phase III clinical studies for the treatment of female sexual dysfunction for investor conferences

Visit this company: www.biosantepharma.com
LINCOLNSHIRE, Ill. - October 26, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reports it will present at the Oppenheimer Healthcare Conference being held in New York on November 2-3, 2010, and the Singular Research Conference being held on November 4, 2010 in Los Angeles.

Stephen M. Simes, BioSante's president & chief executive officer, will speak on Wednesday, November 3, 2010 at 10:50 am ET at the Oppenheimer Healthcare Conference. Phillip B. Donenberg, BioSante's senior vice president of finance and CFO will present on Thursday, November 4, 2010 at 1:20 pm PT at the Singular Research Conference.

Messrs Simes and Donenberg will provide a status update on BioSante's lead program, LibiGel® (testosterone gel), in Phase III clinical studies for the treatment of female sexual dysfunction, as well as a general overview of BioSante. A live audio webcast of Mr. Simes' remarks may be accessed at http://www.veracast.com/webcasts/opco/healthcare2010/86205557.cfm and a replay will be available at the same link.

About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.

For more information, please contact:
BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com

Or

For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com

Visit the BPAX showcase profile at Investorideas.com - http://www.investorideas.com/CO/BPAX/
Request News and Info on BPAX - http://www.investorideas.com/Resources/Newsletter.asp

Visit this company: www.biosantepharma.com
Disclosure, Disclaimer: BPAX is a paid advertising client on Investorideas.com.

Published at www.Investorideas.com - Global research by sectors

If you have any questions regarding information in this press release please contact the company listed in the press release.

Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/

Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp